Commentary: Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared With Aspirin Alone in Patients With Coronary and Peripheral Artery Diseases in Italy

類似資料

• Commentary: Beyond 10-year risk: A cost-effectiveness analysis of statins for the primary prevention of cardiovascular disease
  著者:: Aditya Shah, 等
  出版事項: (2022-07-01)
• Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran
  著者:: Zahra Goudarzi, 等
  出版事項: (2025-03-01)
• Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria
  著者:: Monika Russel-Szymczyk, 等
  出版事項: (2019-12-01)
• Cost-effectiveness study of the MitraClip system for mitral regurgitation treatment in inoperable patients
  著者:: E. G. Fedina, 等
  出版事項: (2021-09-01)
• New Anticancer Drugs: Reliably Assessing “Value” While Addressing High Prices
  著者:: David J. Stewart, 等
  出版事項: (2024-04-01)